Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring

Fuminori Sato, Motoyoshi Tsujino, Yasutaka Miyachi, Ikue Ishimoto, Yuka Nagata, Chikara Komiya, Takuya Ohashi, Yukiko Kurosawa, Maya Sakurada, Kenji Nishida, Yoshihiro Ogawa

研究成果: ジャーナルへの寄稿記事

抄録

We evaluated the efficacy of a GLP-1 analogue, liraglutide, using continuous glucose monitoring (CGM). The subjects included 13 patients with type 2 diabetes for which oral antidiabetic agents had been used. The daily mean blood glucose level, SD of the daily blood glucose level, duration of hyperglycemia (blood glucose > 180 mg/d/), mean amplitude of glycemic excursions (MAGE) and J-index were compared before and after treatment with liraglutide. The BMI, duration of diabetes, CPR index and postprandial CPR level were examined in relation to the recovery rate of the mean blood glucose level and the SD. The daily mean blood glucose level significantly improved from 151.0 mg/d/ to 121.0 mg/d/ (median, p = 0.002). The SD of the daily blood glucose level (43.0 mg/d/ to 14.0 mg/d/, p = 0.002), duration of hyperglycemia (23.0 % to 0.0 %, p = 0.002), MAGE (109.0 mg/d/ to 33.0 mg/d/, p = 0.001) and J-index (36.9 to 18.5, p = 0.002) significantly improved. A significantly negative correlation was observed between the recovery rate of the SD and the duration of diabetes. Liraglutide improves the average blood glucose level and also has a positive effect on flattening the blood glucose levels.

元の言語英語
ページ(範囲)430-435
ページ数6
ジャーナルJournal of the Japan Diabetes Society
56
発行部数7
出版物ステータス出版済み - 7 1 2013
外部発表Yes

Fingerprint

Type 2 Diabetes Mellitus
Blood Glucose
Glucose
Cardiopulmonary Resuscitation
Hyperglycemia
Glucagon-Like Peptide 1
Liraglutide
Hypoglycemic Agents

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

これを引用

Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. / Sato, Fuminori; Tsujino, Motoyoshi; Miyachi, Yasutaka; Ishimoto, Ikue; Nagata, Yuka; Komiya, Chikara; Ohashi, Takuya; Kurosawa, Yukiko; Sakurada, Maya; Nishida, Kenji; Ogawa, Yoshihiro.

:: Journal of the Japan Diabetes Society, 巻 56, 番号 7, 01.07.2013, p. 430-435.

研究成果: ジャーナルへの寄稿記事

Sato, F, Tsujino, M, Miyachi, Y, Ishimoto, I, Nagata, Y, Komiya, C, Ohashi, T, Kurosawa, Y, Sakurada, M, Nishida, K & Ogawa, Y 2013, 'Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring', Journal of the Japan Diabetes Society, 巻. 56, 番号 7, pp. 430-435.
Sato F, Tsujino M, Miyachi Y, Ishimoto I, Nagata Y, Komiya C その他. Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Journal of the Japan Diabetes Society. 2013 7 1;56(7):430-435.
Sato, Fuminori ; Tsujino, Motoyoshi ; Miyachi, Yasutaka ; Ishimoto, Ikue ; Nagata, Yuka ; Komiya, Chikara ; Ohashi, Takuya ; Kurosawa, Yukiko ; Sakurada, Maya ; Nishida, Kenji ; Ogawa, Yoshihiro. / Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. :: Journal of the Japan Diabetes Society. 2013 ; 巻 56, 番号 7. pp. 430-435.
@article{f27a2f637adc49cdbe2e1df3955ad8d2,
title = "Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring",
abstract = "We evaluated the efficacy of a GLP-1 analogue, liraglutide, using continuous glucose monitoring (CGM). The subjects included 13 patients with type 2 diabetes for which oral antidiabetic agents had been used. The daily mean blood glucose level, SD of the daily blood glucose level, duration of hyperglycemia (blood glucose > 180 mg/d/), mean amplitude of glycemic excursions (MAGE) and J-index were compared before and after treatment with liraglutide. The BMI, duration of diabetes, CPR index and postprandial CPR level were examined in relation to the recovery rate of the mean blood glucose level and the SD. The daily mean blood glucose level significantly improved from 151.0 mg/d/ to 121.0 mg/d/ (median, p = 0.002). The SD of the daily blood glucose level (43.0 mg/d/ to 14.0 mg/d/, p = 0.002), duration of hyperglycemia (23.0 {\%} to 0.0 {\%}, p = 0.002), MAGE (109.0 mg/d/ to 33.0 mg/d/, p = 0.001) and J-index (36.9 to 18.5, p = 0.002) significantly improved. A significantly negative correlation was observed between the recovery rate of the SD and the duration of diabetes. Liraglutide improves the average blood glucose level and also has a positive effect on flattening the blood glucose levels.",
author = "Fuminori Sato and Motoyoshi Tsujino and Yasutaka Miyachi and Ikue Ishimoto and Yuka Nagata and Chikara Komiya and Takuya Ohashi and Yukiko Kurosawa and Maya Sakurada and Kenji Nishida and Yoshihiro Ogawa",
year = "2013",
month = "7",
day = "1",
language = "English",
volume = "56",
pages = "430--435",
journal = "Journal of the Japan Diabetes Society",
issn = "0021-437X",
publisher = "Japan Diabetes Society",
number = "7",

}

TY - JOUR

T1 - Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring

AU - Sato, Fuminori

AU - Tsujino, Motoyoshi

AU - Miyachi, Yasutaka

AU - Ishimoto, Ikue

AU - Nagata, Yuka

AU - Komiya, Chikara

AU - Ohashi, Takuya

AU - Kurosawa, Yukiko

AU - Sakurada, Maya

AU - Nishida, Kenji

AU - Ogawa, Yoshihiro

PY - 2013/7/1

Y1 - 2013/7/1

N2 - We evaluated the efficacy of a GLP-1 analogue, liraglutide, using continuous glucose monitoring (CGM). The subjects included 13 patients with type 2 diabetes for which oral antidiabetic agents had been used. The daily mean blood glucose level, SD of the daily blood glucose level, duration of hyperglycemia (blood glucose > 180 mg/d/), mean amplitude of glycemic excursions (MAGE) and J-index were compared before and after treatment with liraglutide. The BMI, duration of diabetes, CPR index and postprandial CPR level were examined in relation to the recovery rate of the mean blood glucose level and the SD. The daily mean blood glucose level significantly improved from 151.0 mg/d/ to 121.0 mg/d/ (median, p = 0.002). The SD of the daily blood glucose level (43.0 mg/d/ to 14.0 mg/d/, p = 0.002), duration of hyperglycemia (23.0 % to 0.0 %, p = 0.002), MAGE (109.0 mg/d/ to 33.0 mg/d/, p = 0.001) and J-index (36.9 to 18.5, p = 0.002) significantly improved. A significantly negative correlation was observed between the recovery rate of the SD and the duration of diabetes. Liraglutide improves the average blood glucose level and also has a positive effect on flattening the blood glucose levels.

AB - We evaluated the efficacy of a GLP-1 analogue, liraglutide, using continuous glucose monitoring (CGM). The subjects included 13 patients with type 2 diabetes for which oral antidiabetic agents had been used. The daily mean blood glucose level, SD of the daily blood glucose level, duration of hyperglycemia (blood glucose > 180 mg/d/), mean amplitude of glycemic excursions (MAGE) and J-index were compared before and after treatment with liraglutide. The BMI, duration of diabetes, CPR index and postprandial CPR level were examined in relation to the recovery rate of the mean blood glucose level and the SD. The daily mean blood glucose level significantly improved from 151.0 mg/d/ to 121.0 mg/d/ (median, p = 0.002). The SD of the daily blood glucose level (43.0 mg/d/ to 14.0 mg/d/, p = 0.002), duration of hyperglycemia (23.0 % to 0.0 %, p = 0.002), MAGE (109.0 mg/d/ to 33.0 mg/d/, p = 0.001) and J-index (36.9 to 18.5, p = 0.002) significantly improved. A significantly negative correlation was observed between the recovery rate of the SD and the duration of diabetes. Liraglutide improves the average blood glucose level and also has a positive effect on flattening the blood glucose levels.

UR - http://www.scopus.com/inward/record.url?scp=84882748952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882748952&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84882748952

VL - 56

SP - 430

EP - 435

JO - Journal of the Japan Diabetes Society

JF - Journal of the Japan Diabetes Society

SN - 0021-437X

IS - 7

ER -